Combo Tx superior for polypoidal choroidal vasculopathy

October 9, 2017

(HealthDay)—Combination therapy consisting of ranibizumab plus verteporfin photodynamic therapy (vPDT) is superior to ranibizumab monotherapy for treatment of eyes with polypoidal choroidal vasculopathy (PCV), according to a study published online Oct. 5 in JAMA Ophthalmology.

Adrian Koh, M.D. from Eye and Retina Surgeons in Singapore, and colleagues randomized 322 Asian patients with symptomatic macular PCV to 0.5 mg ranibizumab and vPDT (n = 168; group) or 0.5 mg ranibizumab and sham PDT (n = 154; monotherapy group). Ranibizumab injections were given for three consecutive months, followed by a pro re nata regimen. Participants also received vPDT or sham vPDT on the first day of the trial, followed by a pro re nata regimen based on the presence of active polyps.

The researchers found that at baseline, the overall mean best-corrected visual acuity and mean central subfield thickness were 61.1 letters and 413.3 μm, respectively. Mean improvement at 12 months was 8.3 letters with combination therapy compared with 5.1 letters with monotherapy, demonstrating that combination therapy met the predefined criterion for noninferiority as well as being superior to monotherapy. In terms of complete polyp regression at month 12, combination therapy was also superior to monotherapy. The only serious adverse ocular event was vitreous hemorrhage (combination therapy group, one case; monotherapy group, three cases).

"After 12 months, combination therapy of ranibizumab plus vPDT was not only noninferior but also superior to in best-corrected visual acuity and superior in complete polyp regression while requiring fewer injections. Combination should be considered for eyes with PCV," conclude the authors.

Several authors disclosed financial ties to the pharmaceutical industry, including Novartis Pharma AG, which funded and managed the study.

Explore further: VKA monotherapy linked to reduced MI, stroke risk in A-fib

More information: Abstract/Full Text

Related Stories

VKA monotherapy linked to reduced MI, stroke risk in A-fib

June 20, 2017
(HealthDay)—For patients with atrial fibrillation (AF), vitamin K antagonist (VKA) monotherapy is associated with reduced risk of first-time myocardial infarction (MI) and stroke compared with acetylsalicylic acid (ASA) ...

Long-term ranibizumab beneficial for macular edema

October 11, 2012
(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity (BCVA), according ...

Ranibizumab no better than saline for vitreous hemorrhage

February 1, 2013
(HealthDay)—For patients with vitreous hemorrhage from proliferative diabetic retinopathy (PDR), the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower than expected, ...

Immune checkpoint inhibitor endocrine dysfunction explored

September 29, 2017
(HealthDay)—Patients receiving immune checkpoint inhibitor (ICI) regimens may experience endocrine dysfunction, with increased risk of thyroid dysfunction and hypophysitis for patients on combination therapy, according ...

Pulmonary hypertension combination therapy may lead to greater disease burden

October 22, 2012
Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or combination therapy, excluding ...

Moxifloxacin monotherapy equivalent to antibiotic combo

January 30, 2013
(HealthDay)—Oral monotherapy with moxifloxacin is as efficacious and safe as combination therapy with ciprofloxacin plus amoxicillin/clavulanic acid for treatment of fever in adult patients with cancer and neutropenia who ...

Recommended for you

Researchers report startling glaucoma protein discovery

October 20, 2017
A discovery in a protein associated with glaucoma was so unheard of that for over two years, researchers ran it through a gauntlet of lab tests and published a new research paper on it. The tests validated what they initially ...

Curve-eye-ture: How to grow artificial corneas

October 19, 2017
Scientists at Newcastle University, UK, and the University of California have developed a new method to grow curved human corneas improving the quality and transparency - solely by controlling the behaviour of cells in a ...

Clinical study success for novel contact lens device aimed to improve glaucoma treatment

October 19, 2017
A novel contact lens device developed by University of Liverpool engineers to improve the treatment of glaucoma has been found to reliably track pressure changes in the eye and be wearable by people who took part in its first ...

Study indicates proof of concept for using a surrogate liquid biopsy to provide genetic profile of retinoblastoma tumors

October 12, 2017
Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. Unlike most cancers that are diagnosed ...

Farsighted children struggle with attention, study finds

October 10, 2017
Farsighted preschoolers and kindergartners have a harder time paying attention and that could put them at risk of slipping behind in school, a new study suggests.

New drug reduces rate of progression of incurable eye disease

October 4, 2017
An international study including researchers from the Centre for Eye Research Australia (CERA) has found a way to slow the progression of dry age-related macular degeneration (AMD) - one of the most common causes of vision ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.